Ivabradine exercise tolerance trial

The effect of ivabradine on exercise tolerance in patients with chronic heart failure: a multicenter, open-label, randomized controlled trial - EXCILE-HF trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200281

Enrollment

Registered

2021-01-04

Start date

2021-04-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Ivabradine is started at 2.5mg twice daily.Thereafter, adjust dose in more than 2-weeks interval as needed in a stepwise manner, to achieve and maintain a target resting heart rate while assessing the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are 20 years of age or more with chronic heart failure in New York Heart Association functional classes II and III, a left ventricular ejection fraction lower than 40%, and a resting heart rate of 75 beats per minute or higher in sinus rhythm despite optimal medical therapy for heart failure including beta-blockers.

Exclusion criteria

Exclusion criteria: Patients with congenital heart disease, severe valvular diseases, active myocarditis, myocardial infarction within the previous 8 weeks, ventricular or atrioventricular pacing >40% of 24 hours, persistent atrial fibrillation or flutter, or symptomatic hypotension.

Design outcomes

Primary

Measure	Time frame
Change in peak oxygen consumption (VO2) during cardiopulmonary exercise testing (CPX) from baseline to 12 weeks.	—

Secondary

Measure	Time frame
Time-dependent changes in peak VO2 during CPX (baseline, 12 weeks, 24 weeks)	—

Contacts

Public ContactTsuyoshi Shiga

The Jikei University Hospital

shiga@jikei.ac.jp+81-3-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026